Effects of leukotriene inhibition on pulmonary morphology in rat pup lungs exposed to hyperoxia.
Assisted ventilation is necessary for treating preterm infants with respiratory distress syndrome. Unfortunately, high and prolonged concentrations of oxygen associated with assisted ventilation often lead to pulmonary changes, such as hemorrhage and inflammation. The resulting chronic pulmonary condition is known as bronchopulmonary dysplasia. Pulmonary changes characteristic of this syndrome can be produced in rat pups exposed to high oxygen levels. We exposed 21-d-old rats to room air or continuous 95% oxygen for 7 d and then allocated them into 6 groups to evaluate whether treatment with zileuton and zafirlukast, 2 agents which decrease the effects of leukotrienes, lessened the pulmonary effects of short-term hyperoxia. After 7 d, lung tissue was collected for light and electron microscopy. Pulmonary changes including edema, hemorrhage, alveolar macrophage influx, and Type II pneumocyte proliferation were graded on a numerical scoring system. Compared with controls exposed to hyperoxia [corrected] and saline, rats exposed to hyperoxia and treated with zileuton had significantly reduced levels of alveolar macrophage influx and Type II pneumocyte proliferation, but those exposed to hyperoxia [corrected] and treated with zafirlukast showed no significant reduction in any pulmonary changes. This study helps define pulmonary changes induced secondary to hyperoxia in rat pups and presents new information on the mechanisms of leukotriene inhibition in decreasing the severity of hyperoxic lung injury.
Funk
Amy J
AJ
St Jude Children's Research Hospital, Memphis, TN, USA.
Mandrell
Timothy D
TD
Lokey
Sharon J
SJ
Kosanke
Stanley D
SD
Li
Chin-Shang
CS
Potters
Charles F
CF
D000818:Animals; D000831:Animals, Newborn; D005260:Female; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018496:Hyperoxia / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D007211:Indoles; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology; D008171:Lung Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010100:Oxygen; D048448:Phenylcarbamates; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000627:therapeutic use*
D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D013449:Sulfonamides; D014105:Tosyl Compounds; D010100:Oxygen; C063449:zileuton; D006918:Hydroxyurea; C062735:zafirlukast